- $45.48m
- -$98.90m
Annual balance sheet for Mural Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | — | — | 271 | 144 |
| Net Total Receivables | — | — | 5.55 | 0.051 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 4.24 | 4.82 | 277 | 153 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 30.9 | 28.9 | 24.1 | 14.5 |
| Other Long Term Assets | ||||
| Total Assets | 35.1 | 33.8 | 302 | 169 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 33.2 | 41.6 | 29 | 26.2 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 53 | 55.4 | 37.9 | 28.9 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Unrealized Gain / Loss | ||||
| Other Equity | ||||
| Total Equity | -17.9 | -21.7 | 264 | 141 |
| Total Liabilities & Shareholders' Equity | 35.1 | 33.8 | 302 | 169 |
| Total Common Shares Outstanding |